CD4 and non-small cell lung carcinoma: In this study, we performed a comprehensive systematic analysis of circulating antitumor CD4+ Th1 response across NSCLC clinical stages, using anti-telomerase CD4+ T-cell response as a surrogate marker of antitumor Th1 immunity.